Product Name:2,3-Dihydro-benzo[1,4]dioxine-6-carboxylic acid

IUPAC Name:2,3-dihydro-1,4-benzodioxine-6-carboxylic acid

CAS:4442-54-0
Molecular Formula:C9H8O4
Purity:98%
Catalog Number:CM158112
Molecular Weight:180.16

Packing Unit Available Stock Price($) Quantity
CM158112-25g in stock ưNJ
CM158112-100g in stock ũũǜ
CM158112-500g in stock Ƕŵțũ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:4442-54-0
Molecular Formula:C9H8O4
Melting Point:-
Smiles Code:O=C(C1=CC=C(OCCO2)C2=C1)O
Density:
Catalog Number:CM158112
Molecular Weight:180.16
Boiling Point:339.8°C at 760 mmHg
MDL No:MFCD00463509
Storage:Store at room temperature.

Category Infos

Benzodioxanes
Benzodioxanes are a class of isomeric compounds with the molecular formula C8H8O2. The three isomers of benzodioxane are 1,2-benzodioxane, 1,3-benzodioxane and 1,4-benzodioxane. 1,4-Benzodioxane has long been a versatile template widely used to design molecules with diverse biological activities. Its use spans past decades in medicinal chemistry to today, involving many drug discovery strategies, not excluding the most advanced ones. 1,4-Benzodioxane derivatives have been described as agonists and antagonists of nicotinic, alpha-adrenergic and 5-HT receptor subtypes. 1,4-Benzodioxane derivatives have been also reported as antitumor and antibacterial agents.

Column Infos

NXP800
Nuvectis Pharma announces encouraging preliminary data from the NXP800 phase 1b clinical trial in platinum-resistant ARID1a-mutated ovarian cancer. There is a 33% response rate and 100% disease control rate in patients evaluated for efficacy.
Heat shock transcription factor 1 (HSF1) is critical for tumorigenesis and progression, and is implicated in multiple solid tumors. NXP800 is a potent, clinical stage inhibitor of the HSF1 pathway. The compound activates GCN2 kinase, that phosphorylates the eIF2α and later encodes the ATF4 transcription regulator, resulting in cancer cell death. NXP800 previously gets Fast Track Designation for platinum-resistant, ARID1a-mutated ovarian cancer.